Impact of a multivariate serum-based proteomic test on physician treatment recommendations for advanced non-small-cell lung cancer

Wallace L. Akerley; Alix M. Arnaud; Bibas Reddy; Ray D. Page

doi:10.1080/03007995.2017.1301903

Impact of a multivariate serum-based proteomic test on physician treatment recommendations for advanced non-small-cell lung cancer

Wallace L. Akerley
, Alix M. Arnaud
, Bibas Reddy
, Ray D. Page

Huntsman Comprehensive Cancer Center, Salt Lake City, UT, USA;
Biodesix Inc., Boulder, CO, USA;
The Center for Cancer and Blood Disorder, Fort Worth, TX, USA

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Current Medical Research and Opinion
Volume	33
Issue number	6
DOIs	https://doi.org/10.1080/03007995.2017.1301903
State	Published - Mar 16 2017
Externally published	Yes

Disciplines

Medicine and Health Sciences
Critical Care
Internal Medicine

Access to Document

10.1080/03007995.2017.1301903License: Unspecified

Cite this

@article{dbb1ca6398374d7381cf5af1fed782fc,

title = "Impact of a multivariate serum-based proteomic test on physician treatment recommendations for advanced non-small-cell lung cancer",

author = "Akerley, \{Wallace L.\} and Arnaud, \{Alix M.\} and Bibas Reddy and Page, \{Ray D.\}",

note = "Objective: The VeriStrat 1 (VS) test is intended to help guide treatment decisions for patients with advanced non-small-cell lung cancer (NSCLC) without an EGFR-sensitizing mutation, classifying patients into two categories. Patients classified as VSGood have a favorable prognosis and significant clinical response to EGFR tyrosine kinase inhibitors (TKIs).",

year = "2017",

month = mar,

day = "16",

doi = "10.1080/03007995.2017.1301903",

language = "American English",

volume = "33",

journal = "Current Medical Research and Opinion",

number = "6",

}

TY - JOUR

T1 - Impact of a multivariate serum-based proteomic test on physician treatment recommendations for advanced non-small-cell lung cancer

AU - Akerley, Wallace L.

AU - Arnaud, Alix M.

AU - Reddy, Bibas

AU - Page, Ray D.

N1 - Objective: The VeriStrat 1 (VS) test is intended to help guide treatment decisions for patients with advanced non-small-cell lung cancer (NSCLC) without an EGFR-sensitizing mutation, classifying patients into two categories. Patients classified as VSGood have a favorable prognosis and significant clinical response to EGFR tyrosine kinase inhibitors (TKIs).

PY - 2017/3/16

Y1 - 2017/3/16

UR - https://www.ncbi.nlm.nih.gov/pubmed/28277859

U2 - 10.1080/03007995.2017.1301903

DO - 10.1080/03007995.2017.1301903

M3 - Article

VL - 33

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

IS - 6

ER -

Impact of a multivariate serum-based proteomic test on physician treatment recommendations for advanced non-small-cell lung cancer

Disciplines

Access to Document

Other files and links

Cite this